CIMG Inc., a Nevada-based company listed on the Nasdaq Capital Market, reported significant financial growth for the fiscal year ending September 30, 2025, with total revenues reaching $10.3 million, a 433.5% increase from $1.9 million in the previous fiscal year. This surge in revenue was primarily driven by the introduction of new product lines, including the Homology of Medicine and Food Series and the Computing Power Product Series, which were bolstered by recent acquisitions. The Homology of Medicine and Food Series alone contributed approximately $6.3 million, accounting for 61.7% of total revenue, while the Computing Power Product Series added $3.8 million, representing 36.9% of total revenue.
Despite the substantial revenue increase, CIMG reported a net loss of $4.9 million for the fiscal year, a decrease from the $9 million loss recorded in the previous year. The reduction in net loss was attributed to a significant decrease in operating expenses, which fell by 31.2% to $4.4 million, primarily due to lower labor costs and professional fees. However, the company's gross profit margin declined to 1.22% from 1.67%, reflecting the lower margins associated with the newly acquired product lines.
CIMG has undergone strategic changes, including the sale of its subsidiaries NuZee KOREA Ltd. and NuZee Investment Co., Ltd. in June 2024, and the acquisition of several companies, such as Beijing Xilin and Shanghai Huomao, which have expanded its operational footprint in Asia. The company is focusing on leveraging artificial intelligence and blockchain technologies to enhance its product offerings and improve user growth and brand management. Additionally, CIMG has secured exclusive distribution rights for various Maca products, further diversifying its product portfolio.
Operationally, CIMG has faced challenges related to compliance with Nasdaq listing requirements, having received multiple deficiency notices regarding stockholder equity and timely filings. As of December 2025, the company regained compliance with several Nasdaq rules but remains under scrutiny for its minimum bid price requirement. The company has also highlighted potential risks associated with its operations in China, including regulatory changes and cybersecurity reviews, which could impact its business model and financial performance.
Looking ahead, CIMG aims to continue expanding its product offerings and geographic reach, particularly in the Asian market, where demand for health and wellness products is growing. The company plans to enhance its digital marketing strategies and strengthen its distribution channels to capitalize on emerging market opportunities. However, management has expressed concerns about the need for additional capital to sustain operations and fund future growth initiatives, indicating that the company may seek further financing in the coming year.
About CIMG Inc.
CIMG Inc. is a Nevada-incorporated company focused on sourcing, marketing, and distributing maca-based health and wellness products across Asia and beyond. Its core offerings include dietary supplements, functional foods, and beverages like maca peptide coffee, maca wine, and energy drinks. The company leverages digital marketing, strategic distribution channels, and sustainable sourcing to serve wholesale and retail markets, emphasizing quality, innovation, and global expansion in the natural superfood industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.